ENDO INTERNATIONAL PLC

(ENDP)
  Report
Delayed Nasdaq  -  05/13 04:00:00 pm EDT
1.200 USD   +6.19%
05/09BMO Capital Lowers Price Target for Endo International to $2 From $4, Maintains Market Perform Rating
MT
05/09Barclays Trims Endo International's Price Target to $1 From $2, Maintains Underweight Rating
MT
05/06Piper Sandler Downgrades Endo International to Underweight From Neutral, Lowers PT to $1 From $3
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Endo Reaches Agreement Intended to Settle Florida Governmental Opioid Cases and Claims

01/18/2022 | 07:01am EDT

DUBLIN, Jan. 18, 2022 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it and its wholly-owned subsidiaries Endo Pharmaceuticals Inc. and Endo Health Solutions Inc. have entered into a statewide settlement agreement intended to resolve all government-related opioid claims in Florida.

The settlement, which is subject to certain conditions and contingencies, provides a framework through which Endo and its subsidiaries can fully and finally resolve the opioid-related claims of Florida and its subdivisions in exchange for a total payment of up to $65 million. The Florida settlement includes no admission of wrongdoing, fault or liability of any kind by Endo or its subsidiaries and resolves, among other things, claims against Endo's subsidiaries which were set for trial in Florida state court in April 2022: State of Florida, Office of the Attorney General, Department of Legal Affairs v. Purdue Pharma, L.P., et al. (Case No. 2018-CA-001438) (Fla. Cir. Ct. Pasco County). The settlement value should not be extrapolated to any other opioid-related cases or claims.

The Company is continuing to litigate opioid claims not covered by its settlements and to pursue settlements that it believes are in its best interests while remaining focused on its primary goal of achieving a global settlement. At the same time, Endo is exploring other strategic alternatives, and may seek to implement one or more of those alternatives in the event it is unable to achieve a global settlement. Endo cannot speculate on the likelihood, nature or timing of any outcome.

About Endo International plc
Endo (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Learn more at www.endo.com or connect with us on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
Certain information in this press release may be considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and any applicable Canadian securities legislation including, but not limited to, any statements relating to the status or outcome of litigation or settlement discussions. Statements including words or phrases such as "believe," "expect," "anticipate," "intend," "estimate," "plan," "will," "may," "look forward," "intend," "future," "potential" or similar expressions are forward-looking statements. All forward-looking statements in this press release reflect Endo's current expectations of future events based on existing trends and information and represent Endo's judgment only as of the date of this press release. Actual results may differ materially and adversely from current expectations based on a number of factors affecting Endo's businesses, including, among other things, the following: the outcome of our strategic review, contingency planning and any potential restructuring; the timing, impact or results of any pending or future litigation, investigations or claims or actual or contingent liabilities, settlement discussions, negotiations or other adverse proceedings; our ability to satisfy judgments or settlements or pursue appeals including bonding requirements; our ability to adjust to changing market conditions; our ability to attract and retain key personnel; our inability to maintain compliance with financial covenants and operating obligations which would expose us to potential events of default under our outstanding indebtedness; our ability to incur additional debt or equity financing for working capital, capital expenditures, business development, debt service requirements, acquisitions or general corporate or other purposes; our ability to refinance our indebtedness; a significant reduction in our short-term or long-term revenues which could cause us to be unable to fund our operations and liquidity needs or repay indebtedness. The occurrence or possibility of any such result has caused us to engage, and may result in further engagement in strategic reviews that ultimately may result in our pursuing one or more significant corporate transactions or other remedial measures, including on a preventative or proactive basis. Those remedial measures could include a potential corporate reorganization, restructuring or bankruptcy filing involving all or a portion of our business, asset sales or other divestitures, cost-saving initiatives, corporate realignments or strategic partnerships. Some of these measures could take significant time to implement and others may require judicial or other third-party approval. Any such actions may be complex, could entail significant costs and charges or could otherwise negatively impact shareholder value, and there can be no assurance that we will be able to accomplish any of these alternatives on terms acceptable to us, or at all, or that they will result in their intended benefits. Therefore, the reader is cautioned not to rely on these forward-looking statements. Endo expressly disclaims any intent or obligation to update these forward-looking statements, except as required to do so by law. Additional information concerning risk factors, including those referenced above, can be found in press releases issued by Endo, as well as Endo's public periodic filings with the U.S. Securities and Exchange Commission and with securities regulators in Canada, including the discussion under the heading "Risk Factors" in Endo's most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q or other filings with the U.S. Securities and Exchange Commission.

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/endo-reaches-agreement-intended-to-settle-florida-governmental-opioid-cases-and-claims-301462370.html

SOURCE Endo International plc


ę PRNewswire 2022
All news about ENDO INTERNATIONAL PLC
05/09BMO Capital Lowers Price Target for Endo International to $2 From $4, Maintains Market ..
MT
05/09Barclays Trims Endo International's Price Target to $1 From $2, Maintains Underweight R..
MT
05/06Piper Sandler Downgrades Endo International to Underweight From Neutral, Lowers PT to $..
MT
05/06Top Midday Decliners
MT
05/06Endo International Posts Lower Q1 Adjusted Earnings, Revenue; Issues Q2 Guidance; Share..
MT
05/06ENDO INTERNATIONAL PLC Management's Discussion and Analysis of Financial Condition and..
AQ
05/06Wall Street Set for Downbeat Session; US Jobs Report Shows Strong Gain
MT
05/06Top Premarket Decliners
MT
05/06TRANSCRIPT : Endo International plc, Q1 2022 Earnings Call, May 06, 2022
CI
05/05ENDO : Q1 Earnings Snapshot
AQ
More news
Analyst Recommendations on ENDO INTERNATIONAL PLC
More recommendations